Avalon GloboCare shares are trading higher after the company announced the extension of its exclusive distribution agreement with Qi Diagnostics to distribute the KetoAir Breathalyzer Device and related accessories in North America, South America, the United Kingdom and the EU.
Portfolio Pulse from Benzinga Newsdesk
Avalon GloboCare shares surged following the announcement of the extension of its exclusive distribution agreement with Qi Diagnostics for the KetoAir Breathalyzer Device and related accessories in North America, South America, the UK, and the EU.
March 28, 2024 | 4:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Avalon GloboCare's stock is likely to experience a positive short-term impact due to the extension of its exclusive distribution agreement with Qi Diagnostics for the KetoAir Breathalyzer Device.
The extension of the exclusive distribution agreement for the KetoAir Breathalyzer Device is significant for Avalon GloboCare, as it expands its market reach in key regions including North America, South America, the UK, and the EU. This expansion is likely to increase the company's revenue potential and market presence, positively impacting its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100